IN2014DN09791A - - Google Patents

Info

Publication number
IN2014DN09791A
IN2014DN09791A IN9791DEN2014A IN2014DN09791A IN 2014DN09791 A IN2014DN09791 A IN 2014DN09791A IN 9791DEN2014 A IN9791DEN2014 A IN 9791DEN2014A IN 2014DN09791 A IN2014DN09791 A IN 2014DN09791A
Authority
IN
India
Prior art keywords
conjugates
disclosed
meningococcal
immunogenic
against meningococcal
Prior art date
Application number
Inventor
Che-Hung Robert Lee
Valerian B Pinto
Original Assignee
Us Sec Dep Of Health & Human Services
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Sec Dep Of Health & Human Services, Us Government filed Critical Us Sec Dep Of Health & Human Services
Publication of IN2014DN09791A publication Critical patent/IN2014DN09791A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are meningococcal immunogenic conjugates which can elicit immune responses against meningococcal polysaccharides (PS) from groups A, C, W-135, and Y and group B factor H binding protein (fHbp). The disclosed conjugates also exhibit bactericidal activity against meningococcal A, C, W-135, Y, B, and X serogroups. Also disclosed are improved methods for preparing conjugates, such as immunogenic conjugates, including activation of a polysaccharide with a cyanylation agent at about 4°C.
IN9791DEN2014 2012-05-24 2014-11-19 IN2014DN09791A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651382P 2012-05-24 2012-05-24
PCT/US2013/042428 WO2013177397A1 (en) 2012-05-24 2013-05-23 Multivalent meningococcal conjugates and methods for preparing cojugates

Publications (1)

Publication Number Publication Date
IN2014DN09791A true IN2014DN09791A (en) 2015-07-31

Family

ID=48579502

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9791DEN2014 IN2014DN09791A (en) 2012-05-24 2014-11-19

Country Status (4)

Country Link
US (2) US9427476B2 (en)
CN (1) CN104428008B (en)
IN (1) IN2014DN09791A (en)
WO (1) WO2013177397A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN102356089B (en) 2008-02-21 2014-02-19 诺华股份有限公司 Meningococcal fhbp polypeptides
HUE049695T2 (en) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuvanting meningococcal factor h binding protein
US9427476B2 (en) * 2012-05-24 2016-08-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent meningococcal conjugates and methods for preparing conjugates
CA2876138C (en) * 2012-06-14 2023-09-19 Novartis Ag Vaccines for serogroup x meningococcus
DK3506935T3 (en) 2016-09-02 2024-04-02 Sanofi Pasteur Inc Neisseria meningitidis-vaccine
CN108144056A (en) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 Polyvalent pneumococcal polysaccharide combination vaccine and preparation method thereof
CN107961370B (en) * 2017-03-22 2020-08-11 武汉博沃生物科技有限公司 Multivalent pneumococcal conjugate vaccine and preparation method thereof
GB202016604D0 (en) * 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
CN117643624A (en) * 2024-01-30 2024-03-05 成都康华生物制品股份有限公司 Preparation method of bivalent polysaccharide conjugate vaccine and bivalent polysaccharide conjugate vaccine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (en) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Process for the preparation of nucleic acid constructs
ATE356630T1 (en) 1998-04-03 2007-04-15 Univ Iowa Res Found METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM USING IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINE
ATE362615T1 (en) 2000-03-20 2007-06-15 Massachusetts Inst Technology INORGANIC PARTICLE CONJUGATES
GB0220197D0 (en) 2002-08-30 2002-10-09 Univ Utrecht Refolding method
CA2844154C (en) 2003-08-06 2016-12-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
BRPI0708849B1 (en) 2006-03-17 2022-05-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for the preparation of complex multivalent immunogenic conjugates, said conjugates, and pharmaceutical compositions
CN102356089B (en) 2008-02-21 2014-02-19 诺华股份有限公司 Meningococcal fhbp polypeptides
WO2010109325A2 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2538969A4 (en) 2010-02-22 2013-11-27 Liquidia Technologies Inc Polysaccharide particle vaccines
JP2013521770A (en) * 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine composition
US9427476B2 (en) * 2012-05-24 2016-08-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent meningococcal conjugates and methods for preparing conjugates

Also Published As

Publication number Publication date
US9956278B2 (en) 2018-05-01
US20150110829A1 (en) 2015-04-23
US20160331824A1 (en) 2016-11-17
CN104428008B (en) 2020-10-09
CN104428008A (en) 2015-03-18
US9427476B2 (en) 2016-08-30
WO2013177397A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
IN2014DN09791A (en)
PH12018501517A1 (en) Neisseria meningitidis compositions and methods thereof
EP4286000A3 (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
BR112012007876A2 (en) "ion exchange membranes"
MX2013013111A (en) Multiple antigen presenting immunogenic composition, and methods and uses thereof.
MY167579A (en) Glycoconjugation processes and compositions
WO2015110940A3 (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
MY169837A (en) Immunogenic compositions of staphylococcus aureus antigens
IN2014DN08830A (en)
GB201101665D0 (en) Immunogenic compositions
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MY158438A (en) Antibodies against human angiopoietin 2
MX2019001761A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens.
WO2011098962A3 (en) Anionic polysaccharides functionalised by at least two hydrophobic groups supported by an at least trivalent spacer
AU2013331781A8 (en) Immunogenic composition comprising 1 or more Streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising Protein E and/or PilA from Haemophilus influenzae.
MX357538B (en) Vaccines for serogroup x meningococcus.
MX2018010920A (en) Novel polysaccharide-protein conjugates and process to obtain thereof.
MX2020002084A (en) Peptide conjugates, conjugation process, and uses thereof.
BR112012007877A2 (en) means and methods for producing artificial capsular polysaccharides of neisseria meningitidis
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
WO2015181834A3 (en) Novel semi-synthetic meningococcal conjugate vaccine
MX2013002841A (en) Immunogenic compositions.